Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $16.67.
Several brokerages have issued reports on MGX. Chardan Capital reiterated a "buy" rating and issued a $15.00 price target on shares of Metagenomi in a research note on Wednesday, November 20th. HC Wainwright lifted their target price on shares of Metagenomi from $7.00 to $14.00 and gave the stock a "buy" rating in a report on Tuesday, December 10th.
Read Our Latest Stock Report on Metagenomi
Shares of MGX stock opened at $2.97 on Friday. Metagenomi has a 1 year low of $1.61 and a 1 year high of $12.74. The firm's fifty day moving average price is $2.95 and its two-hundred day moving average price is $2.89.
A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in shares of Metagenomi by 105.8% in the 3rd quarter. Geode Capital Management LLC now owns 338,031 shares of the company's stock valued at $734,000 after buying an additional 173,796 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of Metagenomi by 209.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company's stock worth $296,000 after purchasing an additional 92,468 shares during the last quarter. Fortitude Advisory Group L.L.C. acquired a new stake in Metagenomi during the 4th quarter worth approximately $273,000. Spire Wealth Management bought a new stake in Metagenomi during the 4th quarter worth approximately $267,000. Finally, Novo Holdings A S increased its position in Metagenomi by 3.5% in the 2nd quarter. Novo Holdings A S now owns 1,800,000 shares of the company's stock valued at $7,344,000 after acquiring an additional 60,825 shares during the period.
Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Metagenomi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metagenomi wasn't on the list.
While Metagenomi currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.